These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 19934822

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. VITREOUS PROSTAGLANDIN E2 CHANGES AFTER TOPICAL ADMINISTRATION OF DICLOFENAC 0.1%, INDOMETHACIN 0.5%, NEPAFENAC 0.3%, AND BROMFENAC 0.09.
    Pastore MR, De Giacinto C, Cirigliano G, D'Aloisio R, Addobbati R, Agostinis C, Radillo O, Di Martino G, Di Nicola M, Cecchini P, Tognetto D.
    Retina; 2020 Sep; 40(9):1838-1845. PubMed ID: 31800462
    [Abstract] [Full Text] [Related]

  • 5. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.
    Walters T, Raizman M, Ernest P, Gayton J, Lehmann R.
    J Cataract Refract Surg; 2007 Sep; 33(9):1539-45. PubMed ID: 17720067
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prostaglandin E2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification.
    Bucci FA, Waterbury LD.
    Adv Ther; 2011 Dec; 28(12):1089-95. PubMed ID: 22105509
    [Abstract] [Full Text] [Related]

  • 8. Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing.
    Bucci FA, Waterbury LD.
    Adv Ther; 2009 Jun; 26(6):645-50. PubMed ID: 19568702
    [Abstract] [Full Text] [Related]

  • 9. Effect of topical ketorolac 0.4%, nepafenac 0.1%, and bromfenac 0.09% on postoperative inflammation using laser flare photometry in patients having phacoemulsification.
    Sahu S, Ram J, Bansal R, Pandav SS, Gupta A.
    J Cataract Refract Surg; 2015 Oct; 41(10):2043-8. PubMed ID: 26703278
    [Abstract] [Full Text] [Related]

  • 10. Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (acular LS) and nepafenac 0.1% (nevanac) in patients undergoing phacoemulsification.
    Bucci FA, Waterbury LD, Amico LM.
    Am J Ophthalmol; 2007 Jul; 144(1):146-7. PubMed ID: 17601444
    [Abstract] [Full Text] [Related]

  • 11. Re: Pharmacokinetics and pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.
    Bucci FA, Waterbury LD.
    J Cataract Refract Surg; 2008 Aug; 34(8):1226; author reply 1226-7. PubMed ID: 18655957
    [No Abstract] [Full Text] [Related]

  • 12. Nepafenac: an ophthalmic nonsteroidal antiinflammatory drug for pain after cataract surgery.
    Jones BM, Neville MW.
    Ann Pharmacother; 2013 Jun; 47(6):892-6. PubMed ID: 23715071
    [Abstract] [Full Text] [Related]

  • 13. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac.
    Lindstrom R, Kim T.
    Curr Med Res Opin; 2006 Feb; 22(2):397-404. PubMed ID: 16466612
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Reduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%.
    Schoenberger SD, Kim SJ, Sheng J, Calcutt MW.
    JAMA Ophthalmol; 2014 Feb; 132(2):150-4. PubMed ID: 24264034
    [Abstract] [Full Text] [Related]

  • 16. Concentration and dosing of ketorolac versus bromfenac.
    Gayton J.
    J Cataract Refract Surg; 2009 Jul; 35(7):1319; author reply 1320. PubMed ID: 19545832
    [No Abstract] [Full Text] [Related]

  • 17. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification.
    Almeida DR, Khan Z, Xing L, Bakar SN, Rahim K, Urton T, El-Defrawy SR.
    J Cataract Refract Surg; 2012 Sep; 38(9):1537-43. PubMed ID: 22795976
    [Abstract] [Full Text] [Related]

  • 18. Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye.
    Chastain JE, Sanders ME, Curtis MA, Chemuturi NV, Gadd ME, Kapin MA, Markwardt KL, Dahlin DC.
    Exp Eye Res; 2016 Apr; 145():58-67. PubMed ID: 26474497
    [Abstract] [Full Text] [Related]

  • 19. NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema.
    Warren KA, Bahrani H, Fox JE.
    Retina; 2010 Feb; 30(2):260-6. PubMed ID: 20175270
    [Abstract] [Full Text] [Related]

  • 20. Effects of topical indomethacin, bromfenac and nepafenac on lipopolysaccharide-induced ocular inflammation.
    Bucolo C, Marrazzo G, Platania CB, Romano GL, Drago F, Salomone S.
    J Pharm Pharmacol; 2014 Jul; 66(7):954-60. PubMed ID: 24697218
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.